Market Place
Sourcing Support
All News #Library
Others
Odonate Announces Expected Delisting of Its Stock
07 Jan 2022 //
BUSINESSWIRE
Odonate Announces Planned Return of Capital to Stockholders
17 Nov 2021 //
BUSINESSWIRE
Odonate Therapeutics Announces Financial Results for the Three and Nine Months
10 Nov 2021 //
BUSINESSWIRE
Odonate Therapeutics Announces Financial Results
27 Jul 2021 //
PR NEWSWIRE
Odonate abandons breast cancer chemo drug, closes its doors
23 Mar 2021 //
FIERCE BIOTECH
Those NDA plans Odonate had for mid-`21? They`re being scrapped
22 Mar 2021 //
ENDPTS
Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel
07 Dec 2020 //
BUSINESSWIRE
Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel
07 Dec 2020 //
BUSINESSWIRE
Odonate Therapeutics Announces Public Offering of Shares of Common Stock
26 Aug 2020 //
BUSINESSWIRE
Odonate Therapeutics Announces Public Offering of Shares of Common Stock
26 Aug 2020 //
BUSINESSWIRE
Odonate Announces Positive Top-line Results from CONTESSA, a Ph 3Tesetaxel
24 Aug 2020 //
BUSINESSWIRE
Odonate Announces Financial Results for the Three and Six Months Ended June 30
30 Jul 2020 //
BUSINESSWIRE
Odonate Therapeutics to Present at the Jefferies Virtual Healthcare Conference
29 May 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.